Wolf-Dieter Janthur

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 341 citations

Medicine, Oncology, Pharmacotherapy +13

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni et al. · Annals of Oncology · 2020 · 273 citations · Full text

Medicine, Oncology, Pharmacology +16

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

Sabine Schmid, Dirk Klingbiel, Stefanie Aeppli et al. · Lung Cancer · 2019 · 56 citations

Medicine, Pharmacology, Pharmacotherapy +8

A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Varvara Polydoropoulou et al. · Annals of Oncology · 2019 · 55 citations · Full text

Medicine, Oncology, Pharmacology +16

Comparing Two Imaging Methods for Follow-Up of Lung Cancer Treatment: A Randomized Pilot Study

Franco Gambazzi, Lukas Frey, Matthias Bruehlmeier et al. · The Annals of Thoracic Surgery · 2018 · 26 citations · Full text

Medicine, Oncology, Radiology +13